GlassScriptPhysician profile
Thomas W Bochow
NPI 1497726103
$937.93
in general payments reported to CMS, 2019-2025
19 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.88 · 2020: $20.01 · 2021: $54.25 · 2022: $235 · 2023: $141 · 2024: $105 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.18 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.40 | 2019-2025 | |
| Astellas Pharma US INC | $76.05 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $70.69 | 2022-2023 | Miebo, Xipere, Visudyne |
| Eyepoint US, INC. | $69.96 | 2022 | |
| Genentech USA, INC. | $58.57 | 2020-2022 | |
| Alimera Sciences, INC. | $54.19 | 2022-2023 | Iluvien |
| Ocular Therapeutix, INC. | $54.12 | 2022-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $48.95 | 2019 | |
| Biogen, INC. | $41.43 | 2022 | |
| Rayner Intraocular Lenses Limited | $34.10 | 2025 | Omidria |
| Welch Allyn | $31.14 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $26.02 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $25.79 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.11 | 2021 | |
| Baxter Healthcare | $20.76 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $20.73 | 2024 | Eylea Hd |
| Thea Pharma INC. | $20.37 | 2023 | Iyuzeh |
| Horizon Therapeutics Plc | $17.55 | 2023 | Tepezza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bochow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.